Wells Fargo analyst Derek Archila maintains Kyverna Therapeutics (NASDAQ:KYTX) with a Overweight and raises the price target...

KYV-101 IIT data demonstrate promising clinical activity, including robust CAR T penetration into the central nervous system (C...

Oral presentation to include topline efficacy and safety data for 6 patients with up to 9 months of follow up​Enrollment for re...

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Kyverna Therapeutics (NASDAQ:KYTX) with a Buy and raises the pr...

William Blair starts Kyverna coverage with Outperform, citing KYV-101's potential as the first FDA-approved CAR-T therapy i...

William Blair analyst Sami Corwin initiates coverage on Kyverna Therapeutics (NASDAQ:KYTX) with a Outperform rating.

Kyverna Therapeutics (NASDAQ:KYTX) reported quarterly losses of $(0.97) per share which beat the analyst consensus estimate of ...